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Antimicrobial peptides encompass a number of different classes, including those that are rich in a particular amino acid. An important subset
are peptides rich in Arg and Trp residues, such as indolicidin and tritrpticin, that have broad and potent antimicrobial activity. The importance of
these two amino acids for antimicrobial activity was highlighted through the screening of a complete combinatorial library of hexapeptides. These
residues possess some crucial chemical properties that make them suitable components of antimicrobial peptides. Trp has a distinct preference for
the interfacial region of lipid bilayers, while Arg residues endow the peptides with cationic charges and hydrogen bonding properties necessary for
interaction with the abundant anionic components of bacterial membranes. In combination, these two residues are capable of participating in
cation–π interactions, thereby facilitating enhanced peptide–membrane interactions. Trp sidechains are also implicated in peptide and protein
folding in aqueous solution, where they contribute by maintaining native and nonnative hydrophobic contacts. This has been observed for the
antimicrobial peptide from human lactoferrin, possibly restraining the peptide structure in a suitable conformation to interact with the bacterial
membrane. These unique properties make the Arg- and Trp-rich antimicrobial peptides highly active even at very short peptide lengths. Moreover,
they lead to structures for membrane-mimetic bound peptides that go far beyond regular α-helices and β-sheet structures. In this review, the
structures of a number of different Trp- and Arg-rich antimicrobial peptides are examined and some of the major mechanistic studies are presented.
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Evolution and natural selection have endowed all organisms
with a vast array of tools for survival. This includes ways to
take advantage of the environment around us, as well as
defensive mechanisms to prevent organisms from exploiting
us. One of the systems present as a first line of defence in the
innate immune system are antimicrobial peptides. These small
and diverse peptides were initially isolated in the 1980s, from
frogs and insects and in the former example, have been found
to play a vital role in their survival in bacteria infested swamps
[1,2]. Since then, a large number of additional antimicrobial
peptides have been found virtually everywhere in nature and
there are presently over 800 that have been identified (see
http://www.aps.unmc.edu/AP/main.html). Several of these
peptides possess functions that cover a broad range of
activities. Initially it was observed that antimicrobial peptides
are bactericidal but in the meantime it has been established that
many of them can also possess antiviral [3], antifungal [4,5],
antitumor [6], and immunomodulatory [7,8] activities. In fact,
it has been observed that a single antimicrobial peptide can
exhibit all of these functions [9]. One example of immuno-
modulatory peptides are the β-defensins, which are part of both
the innate and adaptive immune response. They display direct
antimicrobial activity, but they can also bind to chemokine
receptors, stimulating dendritic cells and T cells [10]. This has
led to the discovery that proteins involved in the immune
response are indeed antimicrobial as well. The human
chemokine MIP-3α has higher antimicrobial activities against
both Gram-negative and Gram-positive bacteria than the β-
defensins that bind to the same chemokine receptor [11].
Clearly, antimicrobial peptides and antimicrobial proteins are
more common than originally suspected and come from an
abundance of sources.
Ever since their discovery, researchers have been hopeful
that antimicrobial peptides will help solve the problem of
bacteria becoming resistant towards common antibiotics at an
alarming rate. Vancomycin resistant enterococci (VRE) and
methicillin resistant Staphylococcus aureus (MRSA) are
occurring with increasing frequency and already are of great
concern in hospitals. In the last 25 years, MRSA incidence has
risen by more than 10 times, while VRE has done the same
within the last 15 years (source: Center for Disease Control,
2005). Many of today's antibiotics are rendered ineffective
because they perform their function on a very specific part of the
bacteria. As a result, minute changes to the antibiotic's target are
sufficient to prevent the drug from being effective. For example,
a single amino acid mutation in the S12 ribosomal subunit ofM.
tuberculosis results in resistance against streptomycin [12].Consequently, it has never been more crucial than now for new
antimicrobial agents to be discovered. That is a problem in
itself, though, as the number of newly introduced antibiotics has
been declining steadily, from 16 new compounds during the
period of 1983–1987 to only 7 between 1998 and 2002 [13].
Antimicrobial peptides may one day be able to reverse some of
these trends. Considering that they have been used successfully
in nature for millions of years and are still highly effective
today, they hold great promise. Furthermore, because many of
them have a broad range of effectiveness and perform their
action on the entire cellular membrane, it is believed bacteria
will only develop resistance with great difficulty. Although
some mechanisms of resistance have already been described,
they either involve a major change in membrane composition to
alter the charge and therefore interfere with peptide–target
association or they are highly specific mechanisms that are not
applicable to a large number of antimicrobial peptides [14].
Thus, it remains likely that antimicrobial peptides will be able to
contribute as therapeutic agents. A number of studies have
shown that antimicrobial peptides act in synergy with today's
commonly used antibiotics, and do so against multi-drug
resistant bacteria [15,16]. Therefore, even if the peptides cannot
be used on their own, they can be administered in combination
with today's antibiotics and improve their potency. Another
intriguing aspect about antimicrobial peptides is the fact that
some of them are derived from food proteins [17]. Because they
are already part of our natural diet and known to be tolerated
well, this alleviates the question of toxicity to some extent.
Despite these beneficial aspects, there remain a number of
problems that must still be addressed. Chemical synthesis of
peptides leads to high production costs, which is compounded
by the fact that linear peptides are often easily proteolytically
degraded [18]. In addition, bacterial killing by antimicrobial
peptides has been shown to be able to release endotoxin from
the bacteria, which can lead to septic shock [19]. Nevertheless,
some antimicrobial peptides such as polymyxin and gramicidin
are already in use as topical agents today, proving that such
obstacles may be overcome or circumvented and justifying the
efforts currently under way to develop antimicrobial peptides
for medicinal use.
Antimicrobial peptides have been proposed to achieve their
bactericidal effect in a number of different fashions. In all
cases, an initial interaction with the outer and/or inner
membranes of bacteria is necessary. This first point of
interaction between the peptides and their targets is often also
the site of antimicrobial action, as they interfere with
membrane function to cause bacterial cell death. Membrane
disruption can occur by a number of different mechanisms.
Certain models such as the barrel-stave, toroidal pore, and
Fig. 1. Various models of antimicrobial peptide activity. A, B, and C all start from the same conformation, with the peptides associating with the bacterial membrane
(top left). The red part of the peptide represents a hydrophilic surface, while blue is hydrophobic. (A) In the barrel-stave model, the peptides span the membrane and
form a pore lined with peptides. (B) The carpet model is characterized by the peptides lining up parallel to the membrane surface and forming a peptide carpet, as the
name implies. This is followed by a detergent-like action induced by the peptides that causes pore formation. (C) The toroidal pore model creates pores that contain
peptides as well as lipid molecules that are curved inwards towards the pore in a continuous fashion from the surface of the membrane. The lifetime of these pores is
believed to vary. After transient pore formation, the peptides end up in both leaflets of the bilayer, which presents a mechanism of shuttling the peptides inside. Longer-
lived toroidal pores may have a lethal effect similar to barrel-stave pores; i.e., they dissipate proton gradients, etc. (A, B, and C reproduced with permission from Nature
Reviews Microbiology, [14], copyright 2005 Macmillan Magazines Ltd.). (D) In the molecular electroporation model the cationic peptides associate with the bacterial
membrane and generate an electrical potential difference across the membrane. When the potential difference reaches 0.2 V, it is thought that pores will be generated
through electroporation [20,134]. (E) The sinking raft model proposes that binding of the amphipathic peptides causes a mass imbalance and consequently, an increase
in local membrane curvature. As the peptides self-associate, they sink into the membrane, creating transient pores which result in the peptides residing in both leaflets
after their resolution. (Adapted with permission from [22]. Copyright 2005 American Chemical Society).
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lesser known models such as the molecular electroporation [20]
or the sinking raft model [21,22] may prove to be important to
explain the mechanisms of antimicrobial peptides as well (Fig.
1). Not all antimicrobial peptides are thought to exert their
major action on membranes. An increasing number of peptides
are being described that act on intracellular targets in bacteria,
inhibiting protein-, or cell-wall synthesis, interact with DNA or
RNA or inhibit some sort of enzymatic activity [14]. Such a
breadth of activity stems from a wide range of antimicrobial
peptides that can be classified into seven different groups (see
[23]). One of these classes encompasses peptides with an
unusual composition of regular amino acids. Of particular
interest to this review are peptides with a high content of Trp
and Arg residues, as these residues represent a recurring theme
among many antimicrobial peptides and almost always play
important roles for activity [24,25]. Not only are Trp residues
important in antimicrobial peptides, they play a crucial role in
membrane spanning proteins as well, as Trp has a strong
preference for the interfacial regions of lipid bilayers [26–28].
In addition, Trp residues are involved in protein folding,
forming both native and nonnative hydrophobic contacts even
in denatured proteins to ensure their proper folding [29].
Further testament to the significance of Arg and Trp residues is
the fact that upon screening of a complete combinatorial library
of hexapeptides, peptides rich in these two amino acids were
found to possess the highest antimicrobial activities [30]. This
review will focus on a selection of Trp- and Arg-rich
antimicrobial peptides and examine studies addressing impor-
tant findings for indolicidin, tritrpticin, puroA, combi-1 and
combi-2, as well as the antimicrobial peptides derived from the
food proteins lactoferrin and lysozyme.
2. Role of tryptophan and arginine residues
Arg and Trp residues are found in unusually high proportion
in many antimicrobial peptides. Their roles have been
investigated thoroughly but it is not entirely clear what specific
properties they bring to antimicrobial peptides, apart from theirFig. 2. (A) Schematic of the dumbbell shaped π-electron clouds above and below t
Electrostatic surface of the Trp indole group (bottom) and the line-diagram above. (A
favorable, parallel cation–π interaction between an Arg and a Trp sidechain. Only in
(Reproduced with permission from [33]. Copyright 1997 American Chemical Sociepositive charge and hydrophobic bulk, respectively. For
example, Trp residues have been placed at many different and
contrasting positions on hydrophobicity scales of amino acids
[31]. In certain cases, Trp is considered hydrophobic due to its
uncharged sidechain, while on the other hand, it is observed that
Trp residues do not reside in the hydrocarbon region of lipid
bilayers and consequently it is placed towards the more
hydrophilic side of the scale. Another important factor is the
extensive π–electron system of the aromatic indole sidechain
that gives rise to a significant quadrupole moment (Fig. 2) [32].
A quadrupole moment can be envisioned as two dipole
moments extending perpendicularly out of either side of the
ring plane. That is, their positively charged tails reside close to
the plane of the ring, while the negative charges make up the
ends of the dumbbell-type shape that is formed (Fig. 2).
Because the Trp sidechains do not have a dipole moment and no
other obvious charges, it is often considered as essentially
hydrophobic, when in fact it has a significant quadrupole
moment that cannot be ignored. The π–electron system of Trp
results in negatively charged clouds that can participate in
cation–π interactions that occur in proteins between the
negatively charged electron cloud of any aromatic residue and
various cationic species, such as ions or sidechains of positively
charged amino acids (Fig. 2) [32]. Cation–π interactions are
important in proteins for substrate binding, catalysis, as well as
ion channel activity [33]. For example, human chromodomains
use cation–π interactions between Trp sidechains and methyl-
ated lysine residues for histone recognition [34,35]. An
inspection of high resolution structures in the Protein Data
Bank (PDB) shows that there is a large number of cation–π
interactions [36]. Although many interactions take place
between cationic amino acids and aromatic residues, the
interactions between Arg and Trp are of particular interest to
us. The cation–π interaction can take place in either a parallel or
a perpendicular, T-shaped orientation. The structures in the PDB
reveal that the parallel (i.e. stacked) arrangement between Arg
and Trp residues is preferred and has been shown to be
energetically favorable in aqueous solution (Fig. 2) [36].
Interestingly, in the stacked conformation, the Arg sidechainhe aromatic ring structure. The arrows on the left indicate dipole moments. (B)
and B excerpted with permission from [32]. Copyright 1996 AAAS.). (C) Most
this orientation is the Arg still capable of hydrogen bonding with other species.
ty).
Table 1
Amino acid sequences of Trp containing antimicrobial peptides
Name Sequence a PDB code b
Indolicidin ILPWKWPWWPWRR-NH2 1G89, 1G8C
CP-10A ILAWKWAWWAWRR-NH2
CP-11 ILKKWPWWPWRRK-NH2 1QXQ
CycloCP-11 IC1LKKWPWWPWRRC1K-NH2 1QX9
Tritrpticin VRRFPWWWPFLRR 1D6X
PuroA FPVTWRWWKWWKG-NH2
Combi-1 Ac-RRWWRF-NH2
Combi-2 Ac-FRWWHR-NH2
Cyclo-combi c RRWWRF 1QVL, 1QVK
LfcinB FKC1RRWQWRMKKLGAPSITC1VRRAF 1LFC
LfcinB4–9 RRWQWR-NH2
LfcinH GRRRRSVQWC1AVSQPEATKC2FQW-
-QRNMRKVRGPPVSC2IKRDSPIQC1IQA 1Z6W, 1Z6V
Lfcin4–14 RRWQWRMKKLG 1Y5C
Lfcin4–14Dis C1RRWQWRMKKLGC1-NH2 1Y58
LysH RAWVAWR-NH2
LysC IVSDGNGMNAWVAWR-NH2
a Disulfide bonded cysteines are denoted by subscript numbers.
b No PDB ID indicates there are no coordinates available.
c This peptide is cycylized end-to-end.
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surrounding water molecules as when it is not involved in any
cation–π interactions [37]. This is in contrast to lysines, which
cannot form hydrogen bonds while engaged in cation–π
interactions with an aromatic residue [37,38]. It has been
suggested that this difference is responsible for the increased
activity of Arg containing peptides over Lys substituted
peptides. Cation–π interactions make the entry of Arg into
the hydrophobic environment inside a lipid bilayer energetically
more favorable. The Arg is effectively shielded from the highly
hydrophobic nature of the bilayer by associating with a Trp
residue [32,39].
The fact that Trp residues have a preference for the
interfacial region of lipid bilayers has been well documented
[26–28]. This behaviour is not only seen in membrane
proteins but is also observed in many Trp containing
antimicrobial peptides. An MD simulation of the short peptide
dermaseptin S3 shows the N-terminal region inserting into the
bilayer, with the Trp residue penetrating into the interfacial
layer of the membrane [40]. Other simulations highlight the
importance of Trp residues in membrane–peptide interactions
as well. For example, simulations of pentapeptides show that
the Trp residue can associate with the positively charged
choline headgroups of the lipid bilayer [37]. Studies also show
that Trps form hydrogen bonds with both water and
components of the lipid bilayers when residing in the
interfacial region [37,41]. These hydrogen-bonding partners
are no longer available to the Trp residues when the peptide
inserts further into the hydrocarbon core. Furthermore, the
large, bulky, paddle-like shape of the indole sidechain disrupts
the highly favorable and cohesive hydrophobic interactions of
the lipid acyl chains when it buries deeper into the
hydrocarbon core of a lipid bilayer, leading to high entropic
energy costs [26]. Thus, it has been proposed that the complex
electrostatic nature of the interfacial region of lipid bilayers is
ideal to accommodate the equally complex nature of Trp
residues [26].
Overall, the cationic nature and unique hydrogen bonding
geometry of Arg and the complex properties of Trp seem to
complement each other well for the purposes of antimicrobial
peptides. The cationic charge of Arg provides an effective
means of attracting the peptides to the target membranes and
hydrogen bonding facilitates its interaction with negatively
charged surfaces such as LPS, teichoic acid, or phosphatidyl
glycerol phospholipid headgroups. Trp represents the most
suitable amino acid to enable the peptide's prolonged
association with the membrane. Depending on the peptide in
question, different properties of these residues are utilized. For
example, in puroA it appears that cation–π interactions between
the Trp and Arg residues allow it to penetrate deeper into the
membrane [39]. LfcinB on the other hand, uses Trp solely as a
hydrophobic anchoring force, possibly to aid in threading the
peptide through the membrane towards an intracellular target.
This notion is substantiated by the observation that neither the
hydrogen bonding potential of Trp, nor its amphipathic nature,
are crucial for the activity of LfcinB, but rather its hydrophobic
character [25].3. Cathelicidins
3.1. Indolicidin
Indolicidin belongs to the cathelicidin family of antimicrobial
peptides. These peptides are produced with an N-terminal
propiece similar to the proteinase inhibitor cathelin. While the
N-terminal protein that is co-expressed is conserved, the
antimicrobial peptide can vary greatly in sequence. It is thought
that through natural selection, particular antimicrobial peptides
were selected for, such that their bactericidal properties match
the pathogens commonly present in the host's environment.
Indolicidin was the first Trp-rich antimicrobial peptide discov-
ered and has consequently been studied very thoroughly. It is a
short, 13 amino acid peptide that is amidated at the C-terminus
and contains the highest proportion of Trp residues ever seen
with 39% (Table 1) [42]. In nature, the peptide is found in bovine
neutrophils, from which it was first isolated [42]. Like many
other antimicrobial peptides, it displays activity against a wide
range of targets, such as Gram-positive as well as Gram-negative
bacteria, fungi, and protozoa (Table 2) [43]. The structure of
indolicidin was solved by homonuclear NMR in neutral DPC
and negatively charged SDS micelles [44]. The peptide did not
adopt any classical secondary structure nor did it display the
characteristic amphipathic nature of antimicrobial peptides [44].
Rather, the peptide displayed an extended conformation in both
micelle types with β-turns being the most prominent structural
motifs that were found (Fig. 3) [44]. The peptide was observed to
form a wedge-type shape, with hydrophobic Trp residues in a
trough, flanked by positively charged regions of the peptide [44].
This way the peptide is thought to insert itself into the membrane
with the hydrophobic core making contacts in the interfacial
regions while the flanking parts interact more prominently with
the lipid headgroups. The mechanism of action of indolicidin is
still under debate. It is unlikely that indolicidin acts in a barrel-
Table 2
Known activities of Trp- and Arg-rich antimicrobial peptides
Gram-negative Gram-positive Fungi Ref.
Indolicidin
E. coli S. aureus C. albicans [128,129]
P. aeruginosa S. epidermidis
S. typhimurium
Tritrpticin
E. coli B. subtilis C. albicans [128]
P. aeruginosa S. aureus
S. typhimurium S. epidermidis
PuroA
E. coli S. aureus [39]
PIN-a, PIN-b
A. tumefaciens C. michiganensis A. brassicola [65]
E. coli S. aureus A. pisi
E. carotovora
carotovora
F. culmorum
P. syringae phaseoli V. dahliae
Combi-1, combi-2
E. coli S. aureus C. albicans [73]
S. sanguis
LfcinB a
E. coli B. cereus C. albicans [89,130,131]
K. pneumoniae B. subtilis C. tropicalis
L. monocytogenes C. perfringens C. neoformans
P. aeruginosa L. monocytogenes T. mentagrophytes
P. vulgaris S. aureus T. rubrum
S. enteritidis S. bovis
Y. enterocolitica S. epidermidis
S. haemolyticus
S. hominus
LfcinHb
Acinetobacter sp. S. aureus C. albicans [106,132,133]
E. aerogenes
E. coli
Klebsiella sp.
HEWL
B. bronchiseptica B. subtilis C. albicans [118]
E. coli M. luteus
K. pneumoniae S. aureus
P. aeruginosa S. epidermidis
S. marcescens S. lentus
S. typhimurium S. zooepidemicus
LysC c
E. coli B. subtilis [86]
K. pneumoniae S. aureus
S. marcescens S. zooepidemicus
LysH c
E. coli B. subtilis [86]
K. pneumoniae M. luteus
P. aeruginosa S. aureus
S. marcescens S. epidermidis
S. lentus
S. zooepidemicus
a Organisms shown here were susceptible to peptide fragments of the LysH
sequence presented in Table 1.
b Only organisms susceptible to the sequence in Table 1 listed here, for other
lysoszyme peptides, see [115,118].
c LfcinB also possesses activities not listed here.
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four times the MIC for indolicidin, indicating that indolicidin
must possess another mode of action to kill bacteria [45]. These
results were corroborated when it was shown that indolicidin
causes DNA filamentation in E. coli cells and more recently,when gel retardation assays demonstrated indolicidin's ability to
bind DNA [43,46]. Indolicidin is thought to cross the
membranes into the cytoplasm at concentrations above the
MIC but below the minimal lytic concentration [43]. Amphi-
pathicity provides indolicidin with a hydrophobic surface
important for protein–protein interactions, while the cationic
surface is crucial for its interactions with both the negative
charges on bacterial membranes as well as the negatively
charged phosphate backbone of DNA.
Although indolicidin is an effective antimicrobial peptide,
various attempts have been made to improve its potency. For
example, peptides were synthesized with Trp analogues such
as 3-(2-naphthyl)-Ala, which show that Trp can be replaced by
non-natural amino acids to enhance the activity of indolicidin
[47]. Another research group created dimers and tetramers of
indolicidin by linking the peptides at their C-terminal ends via
lysine residues [48]. Both the dimeric and tetrameric forms of
indolicidin display increased inhibitory activity against HIV-1
integrase [48]. Another study examines modified versions of
indolicidin including a Pro to Ala mutant, CP10A. This
peptide has increased potency against Gram-positive bacteria
and the mutation had a drastic effect on the peptide's structure.
Instead of an extended structure, CP10A adopts a short
amphipathic helix (Fig. 3) [49]. Interestingly, this mutant was
also observed to influence DNA synthesis, suggesting it retains
indolicidin's ability to penetrate into the cytoplasm. Another
mutant, CP11, was created to enhance the overall charge of the
peptide, which improved its activity against Gram-negative
bacteria and made the peptide less hemolytic than indolicidin
[50]. Membrane mimetic assays revealed that the presence of
LPS enhances surface interactions with the indolicidin analog
peptides and suggest that CP10A inserts deeper into the bilayer
due to its increased helical content, while CP11 is less helical
and has a greater positive charge and therefore inserts less
(Fig. 3) [51]. The activity of CP11 was further enhanced
through structure based design, after it was discovered that the
peptide forms a U shaped molecule that can easily be cyclized
by introducing a cysteine residue at either end [52]. Although
both peptides are amphipathic in DPC micelles, cyclo-CP11
shows a more distinct separation into hydrophobic and
hydrophilic regions [52]. While the antimicrobial activities
were found to be largely similar between the cyclized and
linear CP11, the most notable difference is seen in terms of
their half-lives. In the presence of trypsin, linear CP11 has a
half-life of 4 min, while the cyclic peptide has a half-life of
18 min, which allows cyclo-CP11 to remain active for 90 min
even with the protease present [52].
3.2. Tritrpticin
Tritrpticin is another cathelicidin antimicrobial peptide. First
described in pigs, it is 13 amino acids long and as the name
implies, it has three consecutive Trp residues in its sequence
(Table 1) [53]. This gives it an unusually high proportion of Trp
residues (23%), much like indolicidin. Tritrpticin is highly
cationic at neutral pH with four Arg residues. Its sequence is
almost palindromic, containing two cationic residues close to
Fig. 3. (A and B) Structures of indolicidin determined in DPC and SDS micelles, respectively. (C) Linear CP-11 in the presence of DPC micelles. (D) Structure of the
disulfide bonded, cyclic CP-11 as solved in DPC micelles, highlighting the clear segregation of Trp and Arg residues from each other. (E) Tritrpticin as determined by
NMR in SDS micelles showing the wedge shape consisting of hydrophobic amino acids flanked by the hydrophilic residues. (F) PuroA structure in the presence of
SDS micelles. Notice the cation–π arrangement between Trps 5 and 7 and Arg 6 on the left side of the peptide. Trp residues are highlighted in pale-green, Phe is shown
in orange, and Lys and Arg residues are presented in blue color. The disulfide bridges are shown in yellow stick representation. Additionally, in Figs. 4 and 5, His
residues are shown in cyan and Gln in pink.
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the three central Trp residues (Table 1). The peptide was found
to be structurally poorly defined in Tris buffer, but it adopted a
better defined conformation in SDS micelles [54]. This structure
consists of a turn–turn segment that revolves around the two
proline residues (Fig. 3). This way, the peptide adopts an
amphipathic conformation in SDS micelles, resembling a
wedge shape with the Trp residues in the narrow part of the
structure, mediated by two turns and leading to the hydrophilic
side of the peptide which is made up of the Arg residues [54]. In
SDS micelles, the hydrophobic core is defined much better thanthe cationic part of the peptide, which shows a lot of variability
(Fig. 3). The hydrophobic residues were deduced to rest in the
interfacial region of the bilayer based on Trp fluorescence
quenching experiments, while the cationic Arg residues interact
with the anionic surface charges of the bilayer [54]. To adopt an
amphipathic structure, tritrpticin sacrifices many intra-molecu-
lar hydrogen bonds that would be created if it formed a regular
secondary structure such as a helix or a β-sheet. Modeling
tritrpticin as a sheet or helix based on its primary structure, it
becomes obvious that the peptide cannot form an amphipathic
structure in those conformations [54]. The amphipathic
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considering the peptide prefers this conformation over regular
secondary structure and its attendant stabilizing forces. The
driving forces behind the wedge-shaped, amphiphilic structure
are thought to be the Trp residues and the two Phes that all lie in
the same vicinity such that they can rest in the interfacial region
of the membrane (Fig. 3).
The mechanism of tritrpticin involves interactions with the
bacterial membrane, but what exactly occurs is difficult to
resolve. Tritrpticin induces membrane leakage to various
degrees in different types of model membranes [55]. The
peptide interacts more strongly with LUVs made up of partly
negatively charged phospholipids, such as DOPE:DOPG or
DOPC:DOPG mixtures [55]. In contrast, it only causes very
poor leakage of LUVs consisting of DOPC:DOPE. This is in
agreement with a red-edge effect that is observed in
fluorescence experiments, indicating that tritrpticin inserts into
negatively charged membranes more strongly and therefore has
a greater lytic effect [55]. Such membrane insertion by
tritrpticin was postulated to cause positive curvature strain,
which may eventually lead to toroidal pore formation at high
enough peptide concentrations in accordance with the SMH
model [56–60]. This mechanism has been well documented for
the antimicrobial peptide magainin 2 [57]. This theory is
consistent with another study that examined tritrpticin's ability
to form ion channels [61]. It showed that tritrpticin readily
forms pores and induced current jumps in azolectin black lipid
membranes (BLM), exhibiting strong single channel conduc-
tance values, ranging from hundreds to thousands of pS [61].
Early results show that when other BLMs were used without an
overall negative charge, the peptide induced less ion channel
activity [61]. The ion selectivity of channels formed by
tritrpticin was tested as well, revealing that the pores select
for cationic species [61]. Although this is counter-intuitive
considering tritrpticin's high concentration of positively
charged amino acids, it agrees with other research on
antimicrobial peptides. Analogous to magainin 2, when
tritrpticin inserts into the membrane, the three consecutive Trp
residues form a large hydrophobic centre, which causes lateral
pressure that leads to positive curvature strain [55]. During
subsequent pore formation, the interactions of the Arg residues
with the anionic lipid headgroups will pull the lipids along into
the pore, forming a composite pore not only lined with cationic
charges from the peptide's Arg sidechains but also from the
anionic headgroups of the membrane lipids (Fig. 1) [61].
Naturally, it is much more favorable for cationic species to
traverse a pore lined with both anionic and cationic charges
rather than attempting to overcome repulsive electrostatic forces
stemming from cation–cation interactions.
4. Puroindoline
The puroindoline proteins are small, cationic proteins
isolated from wheat seeds [62]. Two isoforms are known to
exist, puroindoline A (PIN-a) and puroindoline B (PIN-b). The
proteins are about 13 kDa in size, contain five disulfide bonds,
and an unusually Trp rich region. They serve two roles in wheatseeds. Firstly, they are responsible for wheat grain hardness [63]
and secondly, they possess antifungal and antibacterial activity
to protect the seeds (Table 2). For example, it has been
demonstrated that transgenic rice that originally did not express
the puroindolines, shows greatly increased resistance to diseases
when expressing the proteins [64]. Puroindolines have been
found to co-localize in the aleurone and the endosperm regions
of seeds [65]. The aleurone surrounds the starchy endosperm and
presents the initial point of invasion for potential pathogens. The
puroindolines are therefore located ideally to protect the seed
from an attack. In nature, the proteins can act cooperatively with
each other and with other peptides such as α-purothionins to
combat pathogens [65,66]. These properties of puroindolines
have made them very interesting for study, especially in regards
to the food industry, as these proteins could potentially be used
as natural food preservatives [65]. This seems to be a viable idea,
considering that puroindolines are still found intact in foods after
both heat treatments and long-term storage, both of which occur
during food production [65].
The Trp-rich regions of the puroindoline proteins have been
isolated as the potential active centres for antimicrobial/
antifungal activity (Table 1) [39]. While the Trp rich region of
PIN-b (puroB) does not possess any antimicrobial activity, the
short 13 residue peptide of the Trp rich region of PIN-a (puroA)
showed antimicrobial activity against both Gram-positive and
Gram-negative bacteria (Table 2) [39]. The structure of this 13
residue peptide was determined in anionic SDS micelles by
homonuclear NMR methods [39]. Although unstructured in
aqueous solution, puroA adopted a well-defined structure in
SDS micelles. The peptide has a helical segment spanning from
Trp8 to Trp10, with the remainder of the peptide forming a coil,
but not adopting any distinct helical conformation (Fig. 3) [39].
Overall, this forms an amphipathic structure with the cationic
sidechains resting on the hydrophilic side, as seen so often in
antimicrobial peptides [39]. An interesting facet of this structure
is that the sidechain of Arg6 rests directly between the two
indole rings of Trps 5 and 7, which is energetically favorable
due to previously described cation–π effects (Fig. 3) [39].
Puroindolines likely interact with phospholipid membranes,
as they show both strong adsorption to phospholipid monolayers
and are purified with a Triton X-114 extraction, highlighting
their interactions with hydrophobic species [62,67]. Studies with
puroA suggest similar interactions with membranes since the
peptide adopts a well defined conformation in SDS micelles and
also because the peptide is capable of inducing calcein leakage
from vesicles [39]. In addition, research on both the full length
protein and on the puroA peptide reveal that puroindoline prefers
negatively charged phospholipids rather than zwitterionic
headgroups, suggesting that electrostatic interactions play an
important role in determining its target [39,68]. Although it
seems apparent that the two species both interact with bacterial
or fungal membranes, it is still uncertain whether the puroA
peptide and the full-length protein act in the same fashion. The
puroA peptide is only 13 residues long and fluorescence
quenching studies reveal that the peptide resides in the interfacial
region of the membrane [39]. This suggests that the peptide
would act in a fashion similar to magainin 2, which promotes
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tions, causes toroidal pore formation [57]. For the intact
puroindoline proteins as well as other thionins, channel
formation has been reported that leads to membrane permeabi-
lization in Xenopus laevis oocytes and is facilitated by a negative
membrane potential [69,70]. Interestingly, the membranes
disintegrate at elevated protein concentrations as the channels
begin to aggregate, similarly to what has been observed in PIN-a
microscopy studies [68]. Thus, it seems that the puroA peptide
has a different mechanism of action than the intact PIN-a protein.
The full-length proteins have been shown to act synergisti-
cally not only with purothionins, but also with each other,
enhancing each other's potency to varying degrees [65]. Small
amounts of PIN-a were found to have large effects on bacteria
after previous exposure to sub-lethal concentrations of PIN-b
and vice versa [65]. It was also pointed out that PIN-a may act in
a different manner from PIN-b; for example, the PIN-b protein
may have an intracellular target [65]. This theory goes well with
the observed synergy between the two proteins. PIN-a is inactive
at 1/3 its MIC, but upon addition of only 5 μg/mL of PIN-b,
almost 90% inhibition is achieved [65]. Thus, PIN-a can be
envisioned as a ‘gate-opener’ for its counterpart, enabling PIN-b
to enter into the cell at lower concentrations than when the latter
is present alone.
5. Combinatorial peptides
The peptides discussed so far have all been discovered and
derived from an organism that naturally produces either the
peptide itself or a protein that gives rise to that particular
peptide. The following two Trp-rich peptides were both derived
in an entirely different fashion, taking advantage of a synthetic
combinatorial library made to potentially screen millions of
soluble hexapeptides in a library [71]. Not only can these
libraries be used to discover novel antimicrobial peptides, they
can also be used to improve the activity of already known
peptides [72]. The two peptides presented here were discovered
as novel antimicrobial peptides and both contain two Trp and at
least two Arg residues, as well as acetylated N-termini and
amidated C-termini (Table 1) [71,73]. The two peptides, named
combi-1 and combi-2, have antibacterial activities similar to
naturally occurring peptides, with IC50's ranging from 5 to
39 μg/mL against most organisms tested [30]. Intriguingly, the
combi-1 sequence is highly reminiscent of the LfcinB active
centre amino acid sequence (see below and Table 1).
Considering that many of the peptides derived from the
screening of synthetic combinatorial libraries resemble those
found in nature, it appears that this is indeed a mechanism of
performing natural selection in vitro.
The structures of combi-1 and combi-2 show pronounced
dependencies on their immediate surroundings. The peptides are
unstructured in aqueous solution, but when introduced to either
zwitterionic DPC or anionic SDSmicelles, the peptides adopt an
ordered structure [74,75]. Not only are the combis sensitive to
the presence or absence of micelles, they also respond to the
particular type of micelle present. Combi-1 is more ordered in
the presence of SDSmicelles than in DPC, while combi-2 showsno such difference (Fig. 4). Combi-1 only adopts an
amphipathic structure in SDS micelles with its three Arg
residues oriented towards one side and the remaining three
hydrophobic residues on the opposite side, unlike combi-2,
which adopts a coiled and amphipathic structure in both micelle
types (Fig. 4) [74,75]. The interaction between the peptide and
the surrounding medium seems to be governed by the sidechains
and their properties, since no hydrogen bonding of the peptide's
backbone was observed [74]. The amphipathic structure of
combi-1 maximizes the number of favorable interactions with
the micelle. The positively charged Arg residues likely attach
the peptide via electrostatic interactions with the SDS head-
groups while the hydrophobic aromatic residues interact with
the interfacial region of the micelle [74]. Although combi-2
adopts an amphipathic structure in both environments, the
structure still displays some subtle, yet significant, differences.
In DPC micelles, the His residue is part of the hydrophobic
portion of the peptide, while in anionic SDS micelles, the His
forms part of the hydrophilic region and interacts with the
negatively charged micelle (Fig. 4) [75]. This indicates that
combi-2, through its His residue, possesses some structural
plasticity that allows it to adapt to different environments.
Combi-1 displays a clear preference for anionic surfaces not
only in NMR studies, but in a number of other experiments as
well. DSC data show that through its pronounced interactions
with anionic lipid headgroups, the peptide changes the
thermotropic phase behaviour of DPPG membranes, while it
is unable to do so with DPPC membranes [74]. DSC
experiments also indicate that both combi peptides form areas
of higher peptide concentration only in the presence of
negatively charged lipids, such as PG and not with zwitterionic
lipids like PC [75]. Fluorescence quenching data further
substantiate this observation since a larger blue-shift is seen in
PG vesicles than PC vesicles, indicating the Trp residues are
buried deeper in the anionic lipids. Clearly, the peptides have a
highly specific and sensitive preference for anionic membrane
surfaces resembling bacterial membranes. Other experiments
provide additional evidence on how these peptides perform their
bactericidal action. Calcein leakage studies indicate that both
combi peptides are very poor at permeabilizing vesicles [75].
Further, the peptides are too short to span the membrane,
indicating that they are unlikely to perform their lethal action
through stable pore formation. Consistent with this finding,
confocal microscopy studies of fluorescein-labeled peptides
show that the combi peptides rapidly penetrate bacterial cells, in
contrast to other peptides that remain on the surface of bacteria,
where they form a peptide layer [75,76]. Taken together, these
data strongly suggest that the peptides utilize their amphipathic
structure to first interact with the membranes and subsequently
aggregate there. How exactly they pass through the membranes
is not known, but one could imagine that they may form
transient toroidal pores that rapidly disintegrate and thereby
move the peptides inside the cell. Spontaneous uptake into the
cell has also been proposed for a number of other short, Arg-rich
cationic peptides (see below) [24,77]. Once inside the cell, the
peptides could interact with an intracellular target similar to the
lysozyme peptides discussed below.
Fig. 4. (A and B) The linear combi-1 peptide in the presence of DPC and SDS, respectively. (C and D) Combi-2 peptide first in DPC and then SDS micelles. In SDS the
His residue orients itself to the hydrophilic face of the peptide, whereas it remains with the aromatic residues in DPC. (E and F) Cyclo-combi in the presence of DPC
and SDS, respectively. Notice the stacking arrangement between the Arg and Trp residues pointing to the bottom right. See Fig. 3 for the amino acid coloring scheme.
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substitutions and modifications have been made to the peptide
[78]. An end-to-end cyclized version of combi-1 (cyclo-combi)
was found to reduce the MIC tenfold (Table 1) [79]. The
structure of the cyclo-peptide indicates that cyclization
enhances the peptide's amphipathicity, largely segregating the
hydrophobic and hydrophilic portions of the peptide above and
below the plane of the ring structure (Fig. 4) [80]. The peptide
adopts a β-sheet structure in micelles, made up of two short β-
turns [80]. The sidechains are well defined for the hydrophobic
residues, while on the opposite side, Arg1 and Arg2 show great
flexibility in both SDS and DPC micelles [80]. As expected,
cyclo-combi orients its hydrophobic residues towards the
micelle core, while both the backbone and Arg sidechains
reside more towards the surface of the micelle [80]. Interest-
ingly, the third Arg is in close proximity to the indole group ofTrp4 in a stacked conformation, which is ideal for cation–π
interactions (Fig 4). The behaviour of the Arg residues in a lipid
bilayer was further investigated by MD simulations where
hydrogen bonding with phospholipid headgroups and snorkel-
ing effects of the Arg residues could be observed [81].
Formation of peptide–lipid aggregates of about one peptide to
eight lipid molecules was also reported, and this requires further
experimental verification [81].
6. Antimicrobial peptides from food proteins
6.1. Lactoferricins
The glycoprotein lactoferrin (LF) which is found in
mammalian milk and other bodily secretions as well as
neutrophils, is a large 80 kDa iron binding protein of the
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time that LF possesses antimicrobial activity, but originally it
was thought that the activity was dependent on the protein's
ability to scavenge iron away from invading bacteria. Even
though its iron binding properties play a role in preventing
biofilm formation [83], it is now known that this is not its only
mechanism of action. When the protein is digested at acidic pH
by proteases such as pepsin that are found in the stomach, the
products yield highly active antimicrobial peptides [84–87]. In
this manner, newborns are protected from pathogenic infec-
tions, since they consume milk from their mother that not only
provides nutrients, but at the same time enhances the
offspring's still under developed defensive machinery. One
of these antimicrobial peptides is lactoferricin (Lfcin), which is
cleaved from the basic N-terminal region of LF. Bovine Lfcin
(LfcinB) has been investigated most extensively since it is the
most active Lfcin found across various species and also the
most readily available (for a comprehensive review, see [9]).
The Lfcin peptides from different species display drastic
sequence differences but still share some similarities. LfcinB
encompasses 25 residues, including two Trp residues at
positions 6 and 8 and a disulfide bond between its two
cysteine residues (Table 1). Its activity covers a remarkable
range, from antibacterial activity against both Gram-positive
and Gram-negative bacteria to anti-fungal activity, as well as
anti-viral, and antitumor activities (Table 2) [88–90]. In
addition, Lfcin can bind to endotoxin and unmethylated
nucleotides and therefore has been proposed to be capable of
inhibiting septic shock [88]. The 25 amino acid residue peptide
exhibits similar antimicrobial activity to the parent protein and
furthermore, the antimicrobial active center of LF can be
reduced to an even smaller peptide. A 15 residue peptide has
been constructed that only shows minimal loss of activity [91]
and an 11 residue peptide showed decreased hemolytic activity
compared to full length LfcinB, while retaining similar
antimicrobial activity [92]. Finally, what is considered to be
the active center of LfcinB was identified to be a hexapeptide
spanning from residues 4 to 9 and when the C-terminal's
negative charge is neutralized by amidation, this peptide
indeed has an MIC value that is comparable to that of the full-
length 25 residue peptide (Table 1) [93].
The structure of LfcinB in aqueous solution was solved by
homonuclear NMR and shows that the peptide adopts a short,
twisted, antiparallel β-sheet conformation (Fig. 5) [94]. The β-
sheet gives the peptide an amphipathic structure, with most of
the hydrophobic residues residing on one side of the β-sheet
plane, while the majority of the hydrophilic residues rest on the
other side. The hydrophobic residues are nested together tightly,
revealed by a dense cluster of NOEs observed during structure
calculations [94]. The hydrophilic residues, although resting on
one side of the peptide are pointing away from each other,
probably to minimize unfavorable electrostatic repulsions. The
LfcinB structure in solution at low salt concentration contrasts
the conformation of the peptide in the full-length LF protein
(Fig. 5). In the crystal structure, an α-helix stretches over half
the peptide, whereas a β-sheet is present in solution [95]. The
peptide therefore undergoes a major conformational changewhen it is cleaved from LF (Fig. 5). The transition from helix to
sheet has recently been modeled by MD simulations and
highlight two major forces that are responsible for the
interconversion of secondary structure [96]. Firstly, in the
helical conformation the positive charges all lie on the same
side, which makes the peptide quite unstable unless salt is
present to minimize repulsive electrostatic interactions. Sec-
ondly, the conversion appears to also be driven by a
hydrophobic collapse, which favors the β-sheet conformation
when the peptide is excised from LF [96]. As part of the intact
LF protein, the peptide forms a number of stabilizing, long-
range hydrophobic contacts with other parts of the LF protein
[94]. In the short LcinB peptide many hydrophobic sidechains
become exposed to the solvent, which is unfavorable and
therefore leads to a hydrophobic collapse. The structure of the
active center hexapeptide of LfcinB and the 11 residue peptide
(LfcinB4–14) were solved when bound to SDS micelles (Fig. 5)
[97,98]. Neither of the peptides adopts any canonical secondary
structure, but they are both well defined and, not surprisingly,
adopt amphipathic conformations [97,98]. 5-doxyl stearic acid
spin label experiments conducted with the hexapeptide indicate
that the Trp residues are anchored in the interfacial region of the
micelle while the three Arg residues protrude to interact with the
negative charges of the SDS micelles [97]. In addition to these
linear peptides, a cyclized analogue of LfcinB4–14 was made by
disulfide bonding two cysteines that were added at both termini
(Table 1) [98]. This peptide displays a similar structure as the
linear version, but had a more clearly defined segregation of
hydrophilic and hydrophobic residues, which has been credited
for the cyclic peptide's increased antimicrobial activity [98].
Mutational studies on a 15 residue LfcinB peptide provide
interesting insights as well. The replacement of either Trps 6 or
8 by Ala deletes its entire antibacterial activity [99].
Replacement by unnatural amino acids such as β-diphenylala-
nine that possess larger hydrophobic groups or increasing the
number of Trp residues decreases the MICs against E. coli and
S. aureus in most cases [100,101]. This trend is not followed
indefinitely, as increasing the hydrophobic content too much
eventually leads to increased hemolytic activity. These studies
demonstrate the importance of Trp's anchoring ability and
sidechain size and shape, rather than its hydrogen bonding
ability and amphipathic character [25].
Human Lfcin (LfcinH) is significantly larger than the bovine
peptide, consisting of 49 amino acids and possessing a similar
loop to LfcinB that is constrained by a disulfide bond (Table 1).
Its peptide sequence was recently determined by NMR, Edman
degradation and mass spectrometry analysis, following pepsin
digestion of human LF from milk [102]. Originally, another
preparation yielded a slightly different product, that contained
two separate fragments held together by an additional disulfide
bond [87]. The structure of LfcinH is poorly defined in SDS and
DPC micelles, but exhibits a partially folded structure in water
and is well defined in a more hydrophobic solvent consisting of
4:4:1 methanol–chloroform–water [102]. This solvent has been
used in other studies to mimic a membrane environment
[103,104]. In this solvent, LfcinH adopts an amphipathic,
partially helical structure (Fig. 5) [102]. This, unlike LfcinB, is
Fig. 5. (A and C) Ribbon diagrams taken from the crystal structures of intact bovine and human lactoferrin, respectively. Each fragment corresponds to the amino acid
range of the matching lactoferricin peptide. (B and D) Bovine and human lactoferricin peptides, determined in water and membrane mimetic solvents, respectively.
LfcinB undergoes a clear transition is secondary structure from helix to sheet, while LfcinH retains a partially helical conformation. (E) Structure of the LfcinB active
centre hexapeptide as determined in SDS micelles. (F) The slightly longer LfcinB4–14 peptide solved in SDS micelles. Notice the similarity in conformations between
the two. For an explanation of the color scheme, see Fig. 3.
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human LF [105]. In intact human LF, the segment
corresponding to LfcinH forms an α-helix and the first strand
of a larger β-sheet (Fig. 5). The peptide does not form a β-
strand in any solvents tested and does not adopt any helical
structure in an aqueous environment to prevent unfavorable
contacts by hydrophobic residues, such as Phe21 or Val35, with
the hydrophilic solvent [102]. Rather, LfcinH undergoes a
hydrophobic collapse, which is reflected by a significant
number of NOEs observed in water. The highest number of
long range interactions in this partially folded state are observed
for Trps 9 and 23, which reinforces the important role Trpresidues play along the protein folding pathway (Fig. 6) [102].
In a more lipophilic solvent, such as the one mentioned above,
and in the intact human LF protein, the peptide forms stabilizing
hydrophobic contacts with the solvent or the rest of the protein,
respectively, that favor helix formation. Another study involv-
ing the N-terminal part of the LfcinH peptide bound to
endotoxin reveals that the peptide may after all be able to
undergo a similar transition as LfcinB, since the LPS bound
peptide displays CD spectra reminiscent of a β-sheet peptide
[106]. It has yet to be determined what exact effect LPS binding
has on LfcinB and what implications any potentially induced
structural changes have on antimicrobial activity.
Fig. 6. Number of non-sequential, interresidue NOE interactions of LfcinH observed in water. Trps 9 and 23 display the highest number of interactions in the only
partially folded peptide. (Reproduced with permission from [102], © 2006, the American Society for Microbiology. All rights reserved).
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earlier. LfcinB has a broad range of action against many
microbes, while LfcinH is bacteriostatic against a number of
Gram-positive and Gram-negative species (see [9]). A large
determinant for target selectivity are the electrostatic interactions
between target and peptide. The cationic character of the
peptides and the negatively charged membranes of bacteria (i.e.
through PG, LPS, teichoic acid) provide an ideal interaction to
attract the peptides to these cells. Although electrostatic forces
are important for selectivity and the interactions of peptides and
membranes, it does not appear that the Lfcins actually perform
their activity by disrupting the membrane. Vesicle leakage
studies conducted on the LfcinB peptides show that they only
poorly induce leakage, especially when compared to other
antimicrobial peptides that are known to kill bacteria through
membrane disruption, such as tritrpticin [55,98]. Lfcins do,
however, interact with negatively charged membranes. DSC
results show that negatively charged DPPG liposomes display
subtle changes upon LfcinB binding, while DPPE and DPPC
liposomes remain unaffected even at high peptide to lipid ratios
[24]. Both the human and bovine Lfcins are capable of binding
LPS, indicating that they do interact with the outer membrane at
least in Gram-negative bacteria. In fact, an 11 residue peptide of
LfcinH has been shown to form ordered aggregates when LPS is
present, which could create a large amphipathic structure that
has an increased ability to disrupt the outer membrane and
through this membrane damaging effect, permits individual
peptides to move across [106]. This theory is supported by a lag
time in bacterial action that is observed and corresponds to the
time needed for peptide aggregation, as well as by blister-like
formations in the outer membrane of Gram-negative bacteria,
known as blebs [88,106,107]. Therefore, it is likely that Lfcins
are able to interact with the membranes, but it is unlikely that
their major function is to cause pores in the cytoplasmicmembrane. Rather, it seems the Lfcins act on intracellular
targets, which interferes with the normal functioning of
microorganisms. LfcinB transmission electron microscopy
data shows that the peptide indeed moves into the cytoplasm
of both S. aureus as well as E. coli and that the cytoplasmic
components are only affected after bleb formation [107,108].
This is supported by DSC heating scans on DiPoPE bilayers,
which undergo a phase transition from a bilayer to a hexagonal
phase at about 43.5 °C under normal conditions. Upon addition
of LfcinB or its active center, the temperature of this phase
transition increases, similar to what is observed with magainin 2
[24,57]. This pattern is consistent with transient toroidal pore
formation, resulting in the peptide being moved inside the cell.
The two Trp residues are particularly important in LfcinB,
mutating either of them results in a complete loss of
antimicrobial activity [99]. Trp anchors the peptide in the
membrane and presents a vital interaction with the membrane to
facilitate the peptide's entry into the cell. It has actually been
proposed that the Lfcin peptide region acts as a “tugboat” that
pulls the intact LF protein into the cytoplasm, as it has been
observed that even the full-length LF protein can enter cells
spontaneously [109]. This pattern is also seen in a number of
other peptides such as buforin II and penetratin that have short
regions responsible for their spontaneous transfer across the
plasma membrane [110]. These peptides are known as cell-
permeable peptides (CPPs) and interact with the membrane via
electrostatic and/or hydrophobic interactions after which they
may form pores or inverted micelles to shuttle inside the cell
[110]. Similar to antimicrobial peptides, Arg residues and
cation–π interactions play a crucial role in CPP–membrane
interactions. For example, MD studies of penetratin highlight
important cation–π interactions of Trps 48 and 56 and Arg 52 to
shield the peptide from the aqueous phase when interacting with
the membrane [111]. Thus, it appears Lfcin and LF utilize a
1197D.I. Chan et al. / Biochimica et Biophysica Acta 1758 (2006) 1184–1202similar mechanism to enter cells as CPPs and their proteins.
Once inside the cell, LfcinB is capable of binding and affecting
DNA and RNA synthesis in both Gram-negative and Gram-
positive bacteria [112]. LfcinB affects S. aureus in a faster
manner, while in E. coli cells the process takes a longer period of
time, suggesting that the target is more accessible in the former
[112]. The observation that Lfcins act intracellulary helps
explain how these peptides can have such a broad range of target
organisms. As long as an initial favorable electrostatic
interaction takes place between the cationic peptide and anionic
cells of bacteria, fungi, or even tumor cells, the peptide will be
able to traverse themembrane andmove inside where it performs
its activity.
6.2. Lysozyme peptides
Alexander Fleming discovered lysozyme in 1922 and it has
been intensely studied and served as a model protein in many
cases ever since. The protein is found in a range of different
locations, including nasal secretions, tears, milk, as well as
inside the body, stored in neutrophil granulocytes, monocytes,
and macrophages [113]. Lysozyme is best known for its
muramidase action on the peptidoglycan layers of bacterial
membranes. It specifically attacks this compound and breaks it
down enzymatically, thereby destroying the outer membrane
which also kills the bacterial cells. Despite its well documented
properties, it has only recently been observed that the denatured
protein, which lacks the muramidase activity, is still bactericidal
(Table 2) [114]. Furthermore, when the protein is digested by
various proteases, the resulting mixtures are antimicrobial,
reminiscent of the Lfcin peptides. The first such discovery
demonstrated that clostripain digested hen egg white lysozyme
(HEWL) yields a pentadecapeptide spanning over residues 98–
112 (LysC) of the full protein that has antibacterial activity, yet
possesses no muramidase activity (Table 1) [86]. Further studies
have confirmed this, and shown that naturally occurring human
enzymes such as pepsin and trypsin are capable of breaking
down lysozyme to release antimicrobial peptides [115–117].
The homologous region in human lysozyme has been found toFig. 7. (A) LysH structure in SDS micelles, spanning over residues 107–113 in
representing residues 98–112 in HEWL. The well ordered C-terminal region is overla
scheme is the same as the one presented in Fig. 3.possess antimicrobial activity as well [118]. A shorter portion of
the peptide derived fromHEWL, consisting of residues 106–112
retained its activity as long as the Asn residue at the N-terminal
end is mutated to an Arg; incidentally, this gives that particular
stretch of the peptide the same sequence as in human lysozyme
(Table 1) [86]. Two more residues found to be of critical
importance for activity were Trps 108 and 111, mutating only
one of these residues to a tyrosine deletes most of the
antimicrobial activity [86]. The structures of LysC and the
corresponding C-terminal region in human lysozyme (residues
107–113, LysH) were determined recently by homonuclear
NMR in SDS and DPC micelles [119]. The structure of LysC
was also solved in water. The peptides show some differences
from what is seen in the crystal structure of lysozyme as they do
not form the same helix–loop–helix conformation (Fig. 7). The
N-terminal region in LysC is disordered in all three matrices,
while the C-terminal region is well defined [119]. In fact, all
regions corresponding to the C-terminal helix in the full-length
lysozymewere found to bewell ordered in both peptides (Fig. 7).
The two Trp residues in the C-terminal portion of the peptides
stay together on the same side of the peptide in each case, which
enables them to simultaneously interact with the membrane
[119]. LysC exhibits various degrees of α-helicity in the C-
terminal end, which is reminiscent of its conformation in the
crystal structure. The remainder of the well-defined regions in
the C-terminal form coiled structures. Other studies on slightly
different HEWL peptides and the corresponding region in hLZ
reveal that both have strong antimicrobial activity against Gram-
positive and Gram-negative bacteria as well as fungi and that the
N-terminal region is less active than its C-terminal counterpart
[118]. More specifically, the N-terminal segment was mostly
inactive against Gram-negative bacteria, indicating the C-
terminal region is absolutely necessary for activity against
these organisms [118]. Overall, it appears that combined, the N-
terminal helix enters the membrane and forms a pore, while the
C-terminal helix associates with the lipid headgroups, such that
the two Trp residues reside in an interfacial location [118].
Interestingly, the segment cut-out by clostripain in HEWL
corresponds to a helix–loop–helix segment in the full-lengththe full-length human lysozyme protein. (B) LysC peptide in DPC micelles,
id, which is almost identical to the sequence found in the LysH peptide. The color
1198 D.I. Chan et al. / Biochimica et Biophysica Acta 1758 (2006) 1184–1202protein. This secondary structural motif has been observed in
other antimicrobial peptides as well (e.g. cecropin) and is also
seen in other regions of lysozyme. An investigation into any
potential antimicrobial peptides derived from human c-type
lysozyme (cLZ) revealed the presence of four antimicrobial
peptides released through pepsin digestion of cLZ at low pH,
mimicking a newborn's stomach [115]. The four peptides are all
made up of a segment in the N-terminal region of the protein
that constitutes another helix–loop–helix pattern in the protein
[115]. They contain part of the N-terminal domain disulfide
bonded to a short cationic helix in the C-terminal region of the
protein.
LysH interactions with model membranes have been
studied extensively. Confocal microscopy data shows that
the peptide enters the cytoplasm of E. coli and S. aureus cells
shortly after introduction [119]. In support of this finding it
was discovered that other human lysozyme peptides can
spontaneously migrate across the outer and inner membranes
of Gram-negative bacteria, similar to what has been observed
in other cationic, Arg rich peptides such as buforin II as
described above [76,118,120]. Furthermore, the peptide shows
a preference for membranes composed of negatively charged
lipids, stressing the importance of the highly basic nature of
antimicrobial peptides. Experiments conducted with L- and D-
enantiomers of LysH provide further clues on their mechanism
of action. The D-enantiomer has less activity than the L-
enantiomer against a number of organisms tested, while both
enantiomeric peptides show equal behaviour in regards to
membrane association [86,119]. This strongly suggests that
the difference in peptide activity is derived from an
intracellular event, probably involving the peptide and an
intracellular target molecule. In fact, it has been observed that
the short lysozyme peptides inhibit DNA and RNA synthesis
shortly after their introduction to bacterial cells, and only after
this event are the inner and outer membranes further
permeabilized [121]. In summary, it appears that the lysozyme
peptides can cross both the inner and outer membranes,
bringing them inside the cytoplasm of the bacterial cells,
where they affect an intracellular target, likely one involved in
DNA and RNA synthesis, which subsequently leads to the
breakdown of the bacterial membranes and ultimately leads to
cell death.
7. Conclusions
The combi peptides were discovered by scanning all
possible combinations of hexapeptides. Remarkably, the
hexapeptides found to possess the highest levels of activity
were rich in Trp and Arg residues, emphasizing the
importance of these two residues to antimicrobial peptides
[73]. The peptides examined in this paper, as well as newly
described peptides such as Pac-525 [122] or the de novo
designed peptide WLBU2 [123,124], further illustrate this
concept and show that these residues may play an important
role as antimicrobial peptides are being tailored for clinical
use. Additionally, many of the peptides discussed here consist
of very few amino acids. Indolicidin, tritrpticin, and puroAare made up of 13 amino acids, while combi-1 and combi-2,
as well as the active center of LfcinB are 6 amino acids
short. This makes their synthesis cheaper compared to longer
peptides, alleviating some of the concerns regarding peptide
production costs. Another intriguing aspect of these peptides
is the broad range of their activities. Many peptides function
against both Gram-negative and Gram-positive bacteria and
also possess a number of other activities. For example,
LfcinB displays antitumor activity against a number of cancer
cell lines, while it does not affect normal cells [125–127].
LfcinB's ability to distinguish between normal and cancerous
cells is thought to involve the change in surface charge that
occurs in a cancer cell, resulting in cells with a higher
anionic content than normal. This represents a common
theme seen in the peptides discussed, which all depend on
electrostatic interactions between the cationic peptides and
the anionic bacterial surface. Subsequently, the Trps play a
role in membrane association because they preferably interact
with the interfacial region of membranes. Trp residues also
play a key role in protein folding. For example, they form
native or nonnative hydrophobic contacts in unfolded
proteins which serve as nucleation sites during protein
folding [29]. Similarly, this can be applied to antimicrobial
peptides, where in aqueous solution, the Trp residues help
maintain a few hydrophobic contacts which retain the
structure in a conformation favorable for subsequent
membrane interactions.
Food proteins such as lysozyme and lactoferrin bear
particular significance in the field of antimicrobial peptides.
The fact that they represent “nutritional immunity” is exciting
because it is already well known that these proteins are
tolerated by the human body. In many countries today,
lysozyme is used extensively as a natural preservative
amounting to over 100 tons being used for this and similar
purposes [116]. Therefore, these proteins provide an attractive
vehicle for antimicrobial peptides, especially since it has been
discovered that the inactive form can be ingested and
subsequently activated by naturally occurring human or
pathogenic proteases. The latter scenario would provide the
advantage that the antimicrobial peptide is only activated at the
actual location where it is needed. If one of these proteins could
be manipulated to contain a yet to be discovered, perfect
antimicrobial peptide at an enzymatic cut-site, this may just
provide an ideal mechanism for antimicrobial peptide delivery
to certain locations. Such a peptide may just end up being a
Trp- and Arg-rich peptide that displays promiscuity against
pathogenic targets due to the properties of these two residues.
Overall, because of their many advantageous properties, it
appears that Trp and Arg residues are exceedingly suitable to
contribute to potent antimicrobial agents that eventually may be
used on humans.
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